COVID-19
Conditions
Keywords
COVID, mRNA, Vaccine, Placebo, Safety, Immunogenicity
Brief summary
To evaluate the safety and immunogenicity of COVID-19 mRNA vaccine in people aged 18 years and older, 300 participants will be enrolled and divided into two groups: low- and high-dose groups. Each dose group (150 people) will be divided into 2 age groups (75 each):18 to 59 years old and ≥ 60 years old. The subjects will be randomized into vaccine group or placebo group in a ratio of 2:1. Subjects will complete 2 doses of vaccination on Day 0 and Day 21, in which the low-dose group will received 0.3 ml of the study vaccine or placebo, and the high dose group received 0.5 ml of the study vaccine or placebo.
Interventions
BIOLOGICALCOVID-19 mRNA vaccine
2 doses of vaccine on Day 0 and Day 21
BIOLOGICALPlacebo
2 doses of placebo on Day 0 and Day 21
Sponsors
CanSino Biologics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Adults aged 18 years and above with BMI not lower than 18 ; 2. Volunteers are able and willing to comply with the requirements of the clinical trial protocol, and volunteers or witnesses can sign informed consent forms; 3. Willing to discuss the medical history with the investigator or doctor and allow access to all medical records related to this trial; 4. Provide 48-hour PCR negative report; 5. Have not received any other COVID-19 vaccines.
Exclusion criteria
* Criteria for exclusion of the first dose 1. Other medical or psychiatric conditions, including recent (within the past year) or current presence of suicidal ideation/behavior, or laboratory abnormalities that may increase the risk of participating in the study, or subjects who are not suitable to participate in the study according to the investigator's judgment; 2. Positive for human immunodeficiency virus (HIV); 3. History of infection or disease history of Middle East Respiratory Syndrome (MERS), SARS or other coronaviruses or related immunizations; 4. History of serious adverse reactions associated with the vaccine and/or a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine under study; 5. Immunocompromised patients with known or suspected immunodeficiency identified by medical history and/or physical examination; 6. Bleeding constitution or condition associated with prolonged bleeding which investigators believe that intramuscular injection is contraindicated; 7. Women who test positive for blood pregnancy or are breastfeeding, volunteers or their partners have a pregnancy plan within 12 months; 8. Severe hypertension and uncontrollable medication (on-site measurement: systolic blood pressure ≥ 160mmHg, diastolic blood pressure ≥ 100mmHg); 9. Have a serious chronic disease or the condition is in the progression period can not be smoothly controlled, such as diabetes, thyroid disease, etc.; 10. History of severe myocarditis, pericarditis and other heart diseases; 11. Plans to receive other vaccines within 28 days before and after receiving the test vaccine; 12. Those receiving immunosuppressive therapy, including cytotoxic drugs or systemic corticosteroids, such as for cancer or autoimmune diseases, or who were scheduled to receive treatment throughout the study period. If systemic corticosteroids are used in a short period of time (\< 14 days) for the treatment of acute illness, subjects should not enter this study until at least 28 days after corticosteroid therapy has been discontinued prior to study vaccination. Inhalation/spraying, intra-articular, intraskeletal, or topical (skin or eyes) use of corticosteroids is permitted; 13. Receiving blood/plasma products or immunoglobulins 60 days prior to study vaccination or plan to receive for the entire study duration; 14. Engage in other interventional studies within 28 days prior to entering the study and/or during the study's participation; 15. Participated in other interventional studies of lipid-containing nanoparticles; 16. Have symptoms of COVID-19 such as respiratory symptoms, fever, cough, shortness of breath, and dyspnea; 17. Fever, axillary temperature \> 37.0 °C. Second dose
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of wild type neutralizing antibodies | 28 days after complete immunization | GMT of wild type neutralizing antibodies |
| The incidence of adverse reactions (AR) | Within 14 days of each vaccination | To evaluate the incidence of adverse reactions (AR) in all subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of wild type neutralizing antibodies | Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose | Sero-conversation rate of wild type neutralizing antibodies |
| Immunogenicity of anti-S-RBD Ig G antibodies | Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination | Sero-conversation rate of anti-S-RBD Ig G antibodies |
| The incidence of adverse reactions (AR) | Within 28 days of complete immunization | To evaluate the incidence of adverse reactions (AR) in all subjects |
| Changes in laboratory indicators | Before 1st dose and 28 days after second dose | Changes in white blood cell count |
| VOC/VOI serum cross neutralization | 28 days after complete immunization | To evaluated the level of VOC/VOI serum cross neutralization results in all subjects. |
| Cellular immunity | Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination | The response levels and positive rates of IL-2 produced by S protein RBD by ICS in the first 15 subjects in each group |
| The incidence of SAE, MAE and AESI | 12 months after complete vaccination | To evaluation the incidence of SAE, MAE, and AESI in all subjects |
Countries
China
Outcome results
None listed